<DOC>
	<DOCNO>NCT02014467</DOCNO>
	<brief_summary>This study evaluate efficacy safety denosumab 60 milligram ( mg ) 12 month treatment Chinese postmenopausal woman osteoporosis increase risk fracture .</brief_summary>
	<brief_title>Denosumab China Phase III Study</brief_title>
	<detailed_description>The aim Phase III , randomize , double-blind , placebo-controlled , parallel-group study evaluate efficacy safety denosumab ( DMAb ) Chinese postmenopausal woman osteoporosis increase risk fracture . The study design consist two phase : Screening 12-month Double-Blind treatment phase . Following Screening phase , eligible subject randomize receive Double-Blind DMAb ( 60 mg ) Placebo study medication 3:1 ratio . DMAb 60 mg placebo administer single subcutaneous ( SC ) injection begin Double-Blind phase 6 month follow initial dose . All subject receive daily supplementation oral elemental calcium ( least 600 mg ) vitamin D ( least 400 International Units [ IU ] ) . The primary objective determine effect DMAb compare placebo respect mean percent change BMD lumbar spine , measure dual-energy x-ray absorptiometry ( DXA ) , Baseline Month 12 . Secondary objective include evaluation DMAb placebo treatment group : change BMD : lumbar spine ( Month 6 ) , total hip ( Months 6 12 ) , femoral neck ( Months 6 12 ) trochanter ( Months 6 12 ) ; serum biomarkers bone formation resorption ( Months 6 12 ) . Clinical safety denosumab also assess population .</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Subject willing able provide write informed consent . Of Chinese origin define born China , four ethnic Chinese grandparent . Ambulatory woman age 60 90 year , inclusive . The subject BMD absolute value consistent Tscore &lt; 2.5 &gt; 4.0 either lumbar spine total hip . All subject must least one follow additional risk factor : history fracture parental history hip fracture increase bone turnover rate screening ( sCTX &gt; 1.0 SD mean healthy premenopausal woman ) low body weight ( BMI≤19kg/m2 ) elderly ( age≥70y ) current smoker Postmenopausal define &gt; 5 year postmenopausal , &gt; 5 year spontaneous amenorrhea &gt; 5 year post surgical bilateral oophorectomy . Use follicle stimulate hormone ( FSH ) level &gt; 40 mIU/mL confirm surgical postmenopausal status , bilateral oophorectomy status uncertain . Bone/metabolic disease : Any metabolic bone disease , e.g. , osteomalacia osteogenesis imperfecta , may interfere interpretation finding . Paget 's disease Cushing 's disease Hyperprolactinemia Current hyperparathyroidism hypoparathyroidism medical record Thyroid condition : Hyperthyroidism hypothyroidism . Only subject hypothyroidism stable thyroid hormone replacement therapy may allow per follow criterion : If TSH level normal range , subject eligible study . If TSH level elevate ( &gt; 5.5 μIU/mL ≤10.0 μIU/mL ) , serum T4 measure . If serum T4 within normal range , subject eligible . If serum T4 outside normal range , subject eligible study . If TSH level &gt; 10.0 μIU/mL , subject eligible . Rheumatoid arthritis Malignancy : Malignancy ( except fully resect cutaneous basal cell squamous cell carcinoma , cervical breast ductal carcinoma situ ) within last 5years . Malabsorption syndrome : malabsorption syndrome gastrointestinal disorder associate malabsorption , example Crohn 's Disease chronic pancreatitis . Renal disease severe renal impairment Liver disease : Cirrhosis liver Unstable liver disease ( define presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix , persistent jaundice ) , know biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Chronic stable hepatitis B C acceptable subject otherwise meet study entry criterion ( e.g. , presence hepatitis B surface antigen positive Hepatitis C test result within 3 month Screening ) . Drug alcohol abuse : Evidence alcohol substanceabuse within last 12 month investigator believe would interfere understand complete study . Biological abnormality : Any disorder compromise ability subject give write informed consent comply study procedure . Any physical psychiatric disorder , opinion investigator , prevent subject complete study interfere interpretation study result . Known test positive human immunodeficiency virus ( HIV ) . Vitamin D deficiency : Vitamin D deficiency ( 25 ( OH ) vitamin D level &lt; 20 ng/mL ) . Vitamin D repletion permit repletion subject may retested 25 ( OH ) vitamin D level . Oral/Dental Conditions Prior history current evidence osteomyelitis osteonecrosis jaw . Active dental jaw condition require oral surgery . Planned invasive dental procedure . Nonhealed dental oral surgery . Concomitant Medications : Previous strontium IV bisphosphonate : Administration intravenous ( IV ) bisphosphonate , fluoride , strontium osteoporosis within last 5 year . Oral bisphosphonate : Oral bisphosphonate treatment osteoporosis : If use ≥3 year cumulatively , subject ineligible . If use &gt; 3months &lt; 3 year cumulatively : If last dose &lt; 1 year enrolment , subject ineligible . If last dose ≥1 year enrolment , subject eligible . If use ≤3 month , cumulatively , subject eligible . Bone metabolism drug : Administration follow treatment within last 6 week : Parathyroid hormone ( PTH ) PTH derivative , e.g. , teriparatide . Anabolic steroids testosterone . Glucocorticosteroids ( &gt; 5 mg prednisone equivalent per day 10 day ) . Systemic hormone replacement therapy . Selective estrogen receptor modulators ( SERMs ) , e.g. , raloxifene Tibolone . Calcitonin . Calcitriol vitamin D derivative . Other bone active drug include anticonvulsives ( except benzodiazepine ) heparin . Chronic systemic ketoconazole , androgen , ACTH , cinacalcet , aluminum , lithium , protease inhibitor , methotrexate , gonadotropinreleasing hormone agonist . Investigational drug exposure : Currently enrol investigational device drug trial ( ) least 30 day since last study visit investigational device drug trial ( ) , subject receive investigational agent ( ) . Sensitivity : Known sensitivity mammalian cellderived drug product . Clinically significant hypersensitivity denosumab Abnormal laboratory value General : Any laboratory abnormality , opinion investigator , prevent subject complete study interfere interpretation study result . Abnormal serum calcium : current hypocalcemia hypercalcemia . Albumin adjust serum calcium level must within normal limit central laboratory . Liver transaminase : Serum aspartate aminotransferase ( AST ) ≥2.0 x upper limit normal ( ULN ) . Serum alanine aminotransferase ( ALT ) ≥2.0 x ULN . Alkaline phosphatase bilirubin ≥1.5 x ULN ( isolated bilirubin ≥1.5 ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % . DXA measurement : Less two lumbar vertebra evaluable DXA measurement . Height , weight , girth may preclude accurate DXA measurement . Subjects history great 2 vertebral fracture . Subjects high risk fracture must treat active drug opinion investigator .</criteria>
	<gender>Female</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>